58 Results

People

  1. Aghajanian
    Aghajanian
  2. Iasonos
    Iasonos
  3. Konner
    Konner
  4. Kurtz
    Kurtz
  5. Ludwig
    Ludwig
  6. Olson
    Olson
  7. Saltz
    Saltz
  8. Sklarin
    Sklarin
  9. Spriggs
    Spriggs
  10. Bayuga-Miller
    Bayuga-Miller

Groups

  1. Department of Medicine (38)
  2. Solid Tumor Oncology Division (30)
  3. Center for Pancreatic Cancer Research (9)
  4. Survivorship Research (9)
  5. Epidemiology and Biostatistics (8)
  6. Gastrointestinal Oncology Service (8)
  7. Hematologic Malignancies, Division of (8)
  8. Biostatistics Service (7)
  9. Division of Subspecialty Medicine (7)
  10. GSK Faculty (7)
  1. "hypersensitivity"
Formats
  1. Journal Article (48)
  2. Review (4)
  3. Book Section (1)
  4. Conference Paper (1)
  5. Correspondence (1)
  6. Guidelines (1)
  7. Meeting Abstract (1)
  8. Research Letter (1)
Groups
  1. Department of Medicine (38)
  2. Solid Tumor Oncology Division (30)
  3. Center for Pancreatic Cancer Research (9)
  4. Survivorship Research (9)
  5. Epidemiology and Biostatistics (8)
  6. Gastrointestinal Oncology Service (8)

More Groups

People
  1. Carol Aghajanian (4)
  2. Paul Sabbatini (4)
  3. Alexia Iasonos (3)
  4. David Spriggs (3)
  5. Emmy Ludwig (3)
  6. Jason Konner (3)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (4)
  4. 2022 (5)
  5. 2021 (2)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Lancet Oncology (4)
  3. European Journal of Cancer (2)
  4. International Journal of Cancer (2)
  5. International Journal of Gynecological Cancer (2)
  6. Journal of Allergy and Clinical Immunology: In Practice (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. Elsevier Inc. (7)
  3. Lippincott Williams & Wilkins (6)
  4. Elsevier Science, Inc. (5)
  5. Wiley Blackwell (4)
  6. Oxford University Press (3)

More Publishers

Results (58)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Journal Article

    Apolo, A. B.; Powles, T.; Escudier, B.; Burotto, M.; Zhang, J.; Simsek, B.; Scheffold, C.; Motzer, R. J.; Choueiri, T. K.
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity
    Review

    Berretta, M.; Dal Lago, L.; Tinazzi, M.; Ronchi, A.; La Rocca, G.; Montella, L.; Di Francia, R.; Facchini, B. A.; Bignucolo, A.; Montopoli, M.
    Cancers (2022)

    Fulltext@MSK | Save
  • Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States
    Journal Article

    Wang, J. H.; Derkach, A.; Pfeiffer, R. M.; Engels, E. A.
    International Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Simplified graded infusion strategy for mitigation of oxaliplatin hypersensitivity
    Journal Article

    Alonso Martinez, S.; Segal, N. H.; Cercek, A.; Yaeger, R.; Stadler, Z.; Kemeny, N. E.; Nusrat, M.; Shahrokni, A.; Connell, L.; Saltz, L. B.
    Clinical Colorectal Cancer (2022)

    Fulltext@MSK | Save
  • Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001
    Journal Article

    McCoach, C. E.; Rolfo, C.; Drilon, A.; Lacouture, M.; Besse, B.; Goto, K.; Zhu, V. W.; Tan, D. S. W.; Farajian, S.; Potter, L. A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial
    Journal Article

    Bellmunt, J.; Hussain, M.; Gschwend, J. E.; Albers, P.; Oudard, S.; Castellano, D.; Daneshmand, S.; Nishiyama, H.; Majchrowicz, M.; Degaonkar, V.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Letter to the editor regarding clinical debate concerning treatment of pediatric LGG by Cooney et al
    Correspondence

    Karajannis, M. A.; Souweidane, M. M.; Dunkel, I. J.
    Neuro-Oncology Practice (2020)

    Fulltext@MSK | Save
  • Managing toxicities with asparaginase-based therapies in adult all: Summary of an ESMO Open-Cancer Horizons roundtable discussion
    Review

    Burke, P. W.; Hoelzer, D.; Park, J. H.; Schmiegelow, K.; Douer, D.
    ESMO Open (2020)

    Fulltext@MSK | Save
  • Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine
    Journal Article

    Figgins, B.; Primeaux, B.; Shank, B. R.; Chen, S. E.; Weber, D. M.; Lu, H.
    Journal of Oncology Pharmacy Practice (2020)

    Fulltext@MSK | Save